Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher G Wood, MD, FACP
M.D. Anderson Cancer Center
Principal Investigator - Robert Figlin, MD, FACP
Cedars-Sinai Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
125 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Winnipeg, Manitoba, Canada
- Facility name not stated
Hamilton, Ontario, Canada
- Facility name not stated
London, Ontario, Canada
- Facility name not stated
Oshawa, Ontario, Canada
- Facility name not stated
Ottawa, Ontario, Canada
- Facility name not stated
Greenfield Park, Quebec, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Québec, Canada
- Facility name not stated
Hradec Králové, Czechia
- Facility name not stated
Liberec, Czechia
- Facility name not stated
Olomouc, Czechia
- Facility name not stated
Prague, Czechia
- Facility name not stated
Prague, Czechia
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Budapest, Hungary
- Facility name not stated
Debrecen, Hungary
- Facility name not stated
Haifa, Israel
- Facility name not stated
Jerusalem, Israel
- Facility name not stated
Kfar Saba, Israel
- Facility name not stated
Rehovot, Israel
- Facility name not stated
Tel Litwinsky, Israel
- Facility name not stated
Ẕerifin, Israel
- Facility name not stated
Roma, Italy
- Facility name not stated
Rome, Italy
- Facility name not stated
Badalona, Spain
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Seville, Spain
- Facility name not stated
Valencia, Spain
- Facility name not stated
Vigo, Spain
- Facility name not stated
Cambridge, United Kingdom
- Facility name not stated
Norwich, United Kingdom
- Facility name not stated
Preston, United Kingdom
- Facility name not stated
Scottsdale, Arizona, United States
- Facility name not stated
Little Rock, Arkansas, United States
- Facility name not stated
La Jolla, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2012
- Primary completion
- 30 Apr 2018
- Completion
- 30 Apr 2018
- Last update posted
- 14 Jun 2018
- Registered enrollment
- 462
- Registry id
- NCT01582672
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.